v2.4.0.8

Segment reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2013
Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes | The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:
|  | Year ended December 31, |
|  | 2013 |  |  | 2012 |  |  | 2011 |
Segment revenues: |  |  |  |  |  |  |  |  |  |  |  |
U.S. dialysis and related lab services |  |  |  |  |  |  |  |  |  |  |  |
Patient service revenues: |  |  |  |  |  |  |  |  |  |  |  |
External sources |  | $ | 7,998,692 |  |  | $ | 7,299,032 |  |  | $ | 6,462,811 |
Intersegment revenues |  |  | 34,080 |  |  |  | 17,786 |  |  |  | 11,141 |
Total dialysis and related lab services revenues |  |  | 8,032,772 |  |  |  | 7,316,818 |  |  |  | 6,473,952 |
Less: Provision for uncollectible accounts |  |  | (281,146 | ) |  |  | (233,580 | ) |  |  | (190,234 | )
Net dialysis and related lab services patient service revenues |  |  | 7,751,626 |  |  |  | 7,083,238 |  |  |  | 6,283,718 |
Other revenues(1) |  |  | 12,600 |  |  |  | 11,447 |  |  |  | 11,019 |
Total net dialysis and related lab services revenues |  |  | 7,764,226 |  |  |  | 7,094,685 |  |  |  | 6,294,737 |
HCP |  |  |  |  |  |  |  |  |  |  |  |
HCP revenues: |  |  |  |  |  |  |  |  |  |  |  |
External sources |  | $ | 2,919,964 |  |  | $ | 419,431 |  |  | $ | — |
Intersegment revenues |  |  | 250 |  |  |  | — |  |  |  | — |
Total HCP capitated revenues |  |  | 2,920,214 |  |  |  | 419,431 |  |  |  | — |
Net patient service revenues |  |  | 220,251 |  |  |  | 34,407 |  |  |  | — |
Other revenues |  |  | 55,723 |  |  |  | 23,552 |  |  |  | — |
Total revenues |  | $ | 3,196,188 |  |  | $ | 477,390 |  |  | $ | — |
Other – Ancillary services and strategic initiatives |  |  |  |  |  |  |  |  |  |  |  |
Net patient service revenues |  | $ | 75,852 |  |  | $ | 16,824 |  |  | $ | 7,730 |
Capitated revenues |  |  | 67,351 |  |  |  | 61,906 |  |  |  | 45,133 |
Other external sources |  |  | 694,763 |  |  |  | 553,261 |  |  |  | 395,347 |
Intersegment revenues |  |  | 13,916 |  |  |  | 10,481 |  |  |  | 5,796 |
Total ancillary services and strategic initiatives revenues |  |  | 851,882 |  |  |  | 642,472 |  |  |  | 454,006 |
Total net segment revenues |  |  | 11,812,296 |  |  |  | 8,214,547 |  |  |  | 6,748,743 |
Elimination of intersegment revenues |  |  | (48,246 | ) |  |  | (28,267 | ) |  |  | (16,937 | )
Consolidated net revenues |  | $ | 11,764,050 |  |  | $ | 8,186,280 |  |  | $ | 6,731,806 |
Segment operating margin (loss):(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. dialysis and related lab services |  | $ | 1,211,540 |  |  | $ | 1,378,241 |  |  | $ | 1,235,869 |
HCP |  |  | 385,253 |  |  |  | 66,930 |  |  |  | — |
Other—Ancillary services and strategic initiatives |  |  | (38,595 | ) |  |  | (64,877 | ) |  |  | (34,105 | )
Total segment margin |  |  | 1,558,198 |  |  |  | 1,380,294 |  |  |  | 1,201,764 |
Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes: |  |  |  |  |  |  |  |  |  |  |  |
Contingent earn-out obligation adjustment |  |  | 56,977 |  |  |  | — |  |  |  | — |
Corporate support costs(3) |  |  | (65,041 | ) |  |  | (52,457 | ) |  |  | (47,051 | )
Transaction expenses |  |  | — |  |  |  | (30,753 | ) |  |  | — |
Consolidated operating income |  |  | 1,550,134 |  |  |  | 1,297,084 |  |  |  | 1,154,713 |
Debt expense |  |  | (429,943 | ) |  |  | (288,554 | ) |  |  | (241,090 | )
Debt refinancing and redemption charges |  |  | — |  |  |  | (10,963 | ) |  |  | — |
Other income |  |  | 4,787 |  |  |  | 3,737 |  |  |  | 2,982 |
Consolidated income from continuing operations before income taxes |  | $ | 1,124,978 |  |  | $ | 1,001,304 |  |  | $ | 916,605 |
(1) | Includes management fees for providing management and administrative services to dialysis centers in which the Company owns a minority equity investment or which are wholly-owned by third parties.
(2) | Certain costs previously reported in the ancillary services and strategic initiatives have been reclassified to U.S. dialysis and related lab services to conform to the current year presentation.
(3) | Corporate support costs also include $7,721 of an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.
Summary of Assets by Segment | Summary of assets by segment is as follows:
|  | December 31, |
|  | 2013 |  |  | 2012 |
Segment assets |  |  |  |  |  |  |  |
U.S. dialysis and related lab services |  | $ | 10,248,993 |  |  | $ | 9,351,466 |
HCP |  |  | 6,265,767 |  |  |  | 6,228,403 |
Other—Ancillary services and strategic initiatives(1) |  |  | 584,117 |  |  |  | 434,764 |
Consolidated assets |  | $ | 17,098,877 |  |  | $ | 16,014,633 |
(1) | Includes approximately $26 million and $13 million, respectively, of net property and equipment related to the Company’s international operations.

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total profit or loss from reportable segments, to the entity's consolidated income before income taxes, extraordinary items, and discontinued operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration